. 2012;34(1):48–53. doi: 10.5581/1516-8484.20120014

Table 2.

Treatment-related risk of infertility for patients with Hodgkin's lymphoma

Study	n	Disease	Follow-up years	End-point	Treatment	Results (%)	Risks factors
Behringer et al.⁽¹⁰⁾	405	HL	3.2	Amenorrhea	RT	6.3	Alkylating agent, age, disease stage, no oral contraception
					ABVD	3.9
					4 COPP/ABVD	37.5
					8 BEACOPP	22.6
					8 BEACOPP escalated	51.4
Decanter et al.⁽¹³⁾	30	HL and NHL	1	AMH dosage	ABVD	Normal decreased
					Others including alkylating agents	Normal decreased
Hodgson et al.⁽¹¹⁾	36	HL	1	Parenthood	ABVD	Same as controls
Brusamolino et al.⁽¹⁴⁾	67	HL	10	Amenorrhea and parenthood	ABVD	Fertility preserved
Franchi-Rezgui et al.⁽¹⁵⁾	84	HL and NHL	8	Parenthood	Many regimens with alkylating agents	37 preserved fertility	Dose of alkylating, agent and age
Kiserud et al. (16)	91	HL	10	Parenthood	Non-alkylating	55	Dose of alkylating agent and age
					Alkylating (limited number of cycles)	21	Dose of alkylating agent and age
					High-dose chemotherapy and alkylating regimens > 4 cycles	27
De Bruin et al.⁽⁸⁾	518	HL	9.4	Premature menopause	Radiotherapy, MOPP or MOPP/ABV ABVD/EBVP		Highest associations of premature menopause with alkylating agents

Adapted from Harel at al.⁽⁴⁾

HL: Hodgkin's lymphoma; NHL: Non-Hodgkin lymphoma; ABVD: Doxorubicin, bleomycin, vinblastine, dacarbazine; COPP/ABVD: Cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone; EBVP: Epirubicin, bleomycin, vinblastine, dacarbazine; AMH: Anti-Mullerian hormone; RT: Radiation therapy